

CURRICULUM VITAE
Andreea A. Nanci, M.D., M.B.A.

CONTACT INFORMATION

EDUCATION & TRAINING

10/1/88 – 5/12/95 Johann Wolfgang Goethe – University, Medical School in Frankfurt, Germany
Certificate: M.D. Degree

9/1/95 – 2/6/96 House Officer, Leeds General Infirmary
Teaching Hospital of the University of Leeds in Leeds, England

Specialties: Orthopedic (2 months) and General Surgery (3 months)

2/7/96 – 2/4/97 House Officer, Queen Elizabeth and Selly Oak Hospital
Teaching Hospitals of the University of Birmingham
Birmingham, England

Specialties: 1) General Medicine and Geriatrics (3 months each)
 2) Vascular Surgery and Urology (3 months each)

2/17/97 – 3/14/97 House Officer, Private Practice in Frankfurt, Germany
(General Practitioner: Dr.-Medic Belonica Poplicher)
Specialty: Family Medicine

7/1/97 – 6/30/98 Intern, Albert Einstein College of Medicine
Jacobi Medical Center and Einstein Hospital
Internal Medicine
Bronx, New York, USA

7/1/98 – 6/30/00 Resident, Albert Einstein College of Medicine
Jacobi Medical Center and Einstein Hospital
Internal Medicine
Bronx, New York, USA

7/1/00 – 6/30/03 Fellow, University of California, Irvine
Division of Hematology/Oncology, 3-year Fellowship Program
Orange, CA, USA

10/14/03 – 9/30/05 Clinical Fellow, Northwest Hospital
Teaching Hospital of the Johann W. Goethe-University
Division of Hematology/Oncology
Frankfurt, Germany

8/2011 – 8/2013 Healthcare Executive MBA Program
University of California, Irvine, Irvine, CA, USA

PROFESSIONAL POSITIONS

1/1/2006 – 12/31/2013 Solo Private Practice
Hoag Memorial Presbyterian Hospital and Cancer Center

Newport Beach, CA, USA

10/19/2006 – 8/12/2012	Volunteer Assistant Clinical Professor Division of Hematology/Oncology, Department of Medicine University of California, Irvine (UCI) Orange, CA, USA
1/1/2014 – current	UCI Health Community Network Associates Medical Director, UCI Cancer Center – Newport Health Science Clinical Professor Step 3 Division of Hematology/Oncology, Department of Medicine University of California, Irvine

LICENSURE

Licensure:

May 1997	Doctoral License for Germany, <u>Certificate No.:</u> A 970375
May 1997	ECFMG, <u>Certificate No.:</u> 0-471-988-6
April 2000 – current	California State Medical License, <u>Certificate No.:</u> A 71401
October 2000 – current	Drug Enforcement Agency (DEA), <u>Certificate No.:</u> BN6848444

CERTIFICATIONS & EXAMS

Board Certifications:

August 2000	Diplomat, American Board of Internal Medicine (ABIM), <u>Candidate No.:</u> 196086
November 2003	Board Certified in Medical Oncology

Examinations:

September 1990	Physikum (Preclinical Exam in Germany)
August 1991	1. Clinical Exam in Germany
September 1993	USMLE Part I, Score: 218 / 87
March 1994	2. Clinical Exam in Germany
May 1995	3. Clinical Exam in Germany
August 1995	USMLE Part II, Score: 213 / 84
December 1998	USMLE Part III, Score: 208 / 84

MEMBERSHIPS & SOCIETIES

1/2001 – current	Member, American Society of Clinical Oncology (ASCO)
3/2001 – current	Member, American Association for Cancer Research (AACR)
6/2001 – current	Member, American Society of Hematology (ASH)
6/2001 – 6/2004	Member, Career Development Committee at ASCO
7/2015 – current	Member, Medical Oncology Association of Southern California (MOASC)

PROFESSIONAL SERVICE & ACTIVITIES

2011 – 2015	Clinical Informational Technology Governance (CITG) Committee Participation Hoag Memorial Presbyterian Hospital
2013 – 2016	Clinical Informational Technology Chemotherapy Template Creation Committee Hoag Memorial Presbyterian Hospital
2013 – 2017	Komen Foundation Grant Review Committee for Orange County
2017 – current	Clinical Quality Committee Hoag Memorial Presbyterian Hospital

AWARDS & HONORS

June 2000	Ambulatory Care Resident of the Year 1999-2000 Award
-----------	--

January 2003

Young Clinical Investigator Award
The Flight Attendant Medical Research Institute (<http://www.famri.org>)
(Unable to utilize due to move to Germany.)

RESEARCH EXPERIENCE

- 1992 – 1995 Johann W. Goethe University Medical School, Frankfurt, Germany
Department of Nuclear Medicine in Frankfurt / Main
“Antibody Specific Immunotherapy of Ovarian Carcinoma by Induction of Anti – Idiotypic Antibodies”
- 8/24/98 – 10/16/98 Albert Einstein College of Medicine
Department of Anatomy and Structural Biology in Bronx, New York, USA
Advisor: John Condeelis, PhD
“Cell motility of nonmetastatic and metastatic tumor cells visualized in living intact primary tumors using Green Fluorescent Protein (GFP) and isolation of motile tumor cells from live breast tumors”
- 2001 – 2003 University of California, Irvine
Division of Hematology/Oncology
Advisor: Edward L. Nelson, MD, FACP
“DNA immunization and biological adjuvants for augmentation of dendritic cell (DC) function”
- 10/2004 Sub-Investigator in the Open Phase I Repeated Dose Escalation Study of the Polo-like Kinase 1 Inhibitor BI 2536 BS Administered Intravenously in Patients with Advanced Solid Tumors with Repeated Administration in Patients with Clinical Benefit (Multi-center Clinical Trial sponsored through Boehringer Ingelheim)

ACTIVE RESEARCH GRANT and CONTRACT SUPPORT

Clinical Translational Research Activities

UC Irvine Confidential User: MICHEMA1

Protocols By Staff

Search Criteria

Staff Name: nanci Protocol Status: OPEN TO ACCRUAL, CLOSED TO ACCRUAL

Staff Name	Protocol No.	Title	Status	Staff Role	Sponsor	Sponsor Type
Nanci, Andreea	ALLIANCE-A011801	The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib	OPEN TO ACCRUAL	Co-Investigator	Alliance	National
	ALLIANCE-A012103	Optimize-PCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy	OPEN TO ACCRUAL	Co-Investigator	Alliance	National
	ALLIANCE-A041702	A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>= 65 years of age) With Chronic Lymphocytic Leukemia (CLL)	CLOSED TO ACCRUAL	Co-Investigator	Alliance	National
	ALLIANCE-A221505	Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction	CLOSED TO ACCRUAL	Co-Investigator	Alliance	National
	ALLIANCE-A222101	An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy	OPEN TO ACCRUAL	Co-Investigator	Alliance	National
	COG-ANHL1931	A Randomized Phase III Trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma	OPEN TO ACCRUAL	Co-Investigator	CHILDRENS ONCOLOGY GROUP	National

Search Criteria

Staff Name: nanci Protocol Status: OPEN TO ACCRUAL, CLOSED TO ACCRUAL

Staff Name	Protocol No.	Title	Status	Staff Role	Sponsor	Sponsor Type
	ECOG-E1A11	Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)	CLOSED TO ACCRUAL	Co-Investigator	SWOG	National
	ECOG-EAY131	Molecular Analysis for Therapy Choice (MATCH)	CLOSED TO ACCRUAL	Co-Investigator	ECOG-ACRIN	National
	ETCTN-10146	Randomized Phase II Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab + Neoadjuvant Vaccine vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer	CLOSED TO ACCRUAL	Co-Investigator	ETCTN	National
	ETCTN-10287	A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)	CLOSED TO ACCRUAL	Co-Investigator	ETCTN	National
	ETCTN-10538	Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY1 MDS/MPN) a Randomized, Phase II Trial	OPEN TO ACCRUAL	Co-Investigator	ETCTN	National
	ETCTN-10546	Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer	OPEN TO ACCRUAL	Co-Investigator	ETCTN	National
	NRG-BR004	A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Perituzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer	CLOSED TO ACCRUAL	Co-Investigator	NRG Oncology	National
	NRG-BR008	A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*)	CLOSED TO ACCRUAL	Co-Investigator	NRG Oncology	National

Search Criteria

Staff Name: nanci Protocol Status: OPEN TO ACCRUAL, CLOSED TO ACCRUAL

Staff Name	Protocol No.	Title	Status	Staff Role	Sponsor	Sponsor Type
	NRG-BR009	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score <= 25 (OFSET)	OPEN TO ACCRUAL	Co-Investigator	NRG Oncology	National
	NSABP-B-51	A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy	CLOSED TO ACCRUAL	Co-Investigator	NSABP	National
	SWOG-N1048	A Phase III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	CLOSED TO ACCRUAL	Co-Investigator	SWOG	National
	SWOG-S0820	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III (PACES)	CLOSED TO ACCRUAL	Co-Investigator	SWOG	National
	SWOG-S1207	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer	CLOSED TO ACCRUAL	Co-Investigator	SWOG	National
	SWOG-S1418	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >= 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy	CLOSED TO ACCRUAL	Co-Investigator	SWOG	National

Search Criteria

Staff Name: nanci Protocol Status: OPEN TO ACCRUAL, CLOSED TO ACCRUAL

Staff Name	Protocol No.	Title	Status	Staff Role	Sponsor	Sponsor Type
	SWOG-S1609	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	CLOSED TO ACCRUAL	Co-Investigator	SWOG	National
	SWOG-S2007	A Phase II Trial of Sacituzumab govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases	CLOSED TO ACCRUAL	Co-Investigator	SWOG	National
	SWOG-S2206	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.	OPEN TO ACCRUAL	Co-Investigator	SWOG	National
	UCI-14-67	A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting	CLOSED TO ACCRUAL	Co-Investigator	UCI	Institutional
	UCI-16-01	Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer)	CLOSED TO ACCRUAL	Co-Investigator	UCI	Institutional
	UCI-17-43	Blood Collection Protocol for Circulating Tumor Cells and Circulating Cancer Associated Fibroblasts in Breast Cancer Patients	CLOSED TO ACCRUAL	Co-Investigator	UCI	Institutional
	UCI-18-136	Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer	OPEN TO ACCRUAL	Co-Investigator	UCI	Institutional
	UCI-19-145	Phase II, Open-Labeled, Single-Armed Combination Treatment with Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer	OPEN TO ACCRUAL	Co-Investigator	UCI	Institutional

Search Criteria

Staff Name: nanci Protocol Status: OPEN TO ACCRUAL, CLOSED TO ACCRUAL

Staff Name	Protocol No.	Title	Status	Staff Role	Sponsor	Sponsor Type
	UCI-19-88	A Phase III Double-Blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (AI)	CLOSED TO ACCRUAL	Co-Investigator	AstraZeneca	Industry
	UCI-21-185	A Phase III Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)	CLOSED TO ACCRUAL	Co-Investigator	AstraZeneca	Industry
	UCI-21-209	A Phase III Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	CLOSED TO ACCRUAL	Co-Investigator	Loxo Oncology, Inc.	Industry
	UCI-21-212	A Randomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	CLOSED TO ACCRUAL	Co-Investigator	Gilead Sciences, Inc.	Industry
	UCI-21-216	A Phase I/II, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy	OPEN TO ACCRUAL	Co-Investigator	Astellas Pharma Global Development, Inc.	Industry

Search Criteria

Staff Name: nanci Protocol Status: OPEN TO ACCRUAL, CLOSED TO ACCRUAL

Staff Name	Protocol No.	Title	Status	Staff Role	Sponsor	Sponsor Type
	UCI-22-111	EMBER-4: A Randomized, Open-Label, Phase III Study of Adjuvant Imunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	OPEN TO ACCRUAL	Co-Investigator	Eli Lilly	Industry
	UCI-22-114	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer	CLOSED TO ACCRUAL	Co-Investigator	Genentech, Inc.	Industry
	UCI-22-139	A Phase III, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a GSK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy	OPEN TO ACCRUAL	Co-Investigator	Celcuity Inc	Industry
	UCI-22-141	A Phase III Open-label, Randomized Study of Datopotamab Deruxtecán (Dato DXd) with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (D926XC00001; TROPION-Breast03)	CLOSED TO ACCRUAL	Co-Investigator	AstraZeneca	Industry

Search Criteria

Staff Name: nanci Protocol Status: OPEN TO ACCRUAL, CLOSED TO ACCRUAL

Staff Name	Protocol No.	Title	Status	Staff Role	Sponsor	Sponsor Type
	UCI-23-124	A Phase III, Open-Label, Randomised Study of Neoadjuvant Datopotamab Deruxtecán (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer (D926QC00001; TROPION-Breast04)	OPEN TO ACCRUAL	Co-Investigator	AstraZeneca	Industry

UNIVERSITY SERVICE

2014 – current Member, UCI Chao Family Comprehensive Cancer Center

TEACHING EXPERIENCE – CLINICAL

- 12/6/17 UCI Internal Medicine Residency Core Conference: “Adverse Effects of Chemotherapeutic Agents”. Presented at UCI Medical Center.
- 12/7/17 UCI Internal Medicine Residency Core Conference: “Adverse Effects of Chemotherapeutic Agents”. Presented at VA Long Beach Medical Center.
- 10/24/18 UCI Internal Medicine Residency Core Conference: “Platelets Disorders and Hypercoagulable States”. Presented at UCI Medical Center.
- 10/26/18 UCI Internal Medicine Residency Core Conference: “Platelets Disorders and Hypercoagulable States”. Presented at VA Long Beach Medical Center.
- 11/6/19 UCI Internal Medicine Residency Core Conference: “Breast & Ovarian Cancer”. Presented at UCI Medical Center.
- 11/7/19 UCI Internal Medicine Residency Core Conference: “Breast & Ovarian Cancer”. Presented at VA Long Beach Medical Center.

PUBLICATIONS

1. Baum RP, Noujaim AA, **Nanci A**, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, and Hör G. Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13. *Hybridoma* 1993 Oct; 12(5): 583-9. PMID: 8300134. DOI: 10.1089/hyb.1993.12.583.
2. Baum RP, Niesen A, Hertel A, **Nancy (sic) A**, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, and Hör G. Activating Anti-Idiotypic Human Anti-mouse Antibodies for Immunotherapy of Ovarian Carcinoma. *Cancer*. 1994 Feb 1;73(3 Suppl):1121-5. PMID: 8306256.
3. Dillman RO1, **Nanci AA**, Williams ST, Kim RB, Hafer RL, Coleman CL, Wang PC, Duma CM, Chen PV, Selvan SR, Cornforth AN, DePriest C. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. *Cancer Biother Radiopharm*. 2010 Oct;25(5):553-7. doi: 10.1089/cbr.2010.0819. Epub 2010 Sep 19. PMID: 20849310.

ABSTRACTS

1. Hertel A, Baum RP, Nanci A, Schulte L, Suresh MR, Noujaim AA, Donnerstag B, Oltrogge J, and Hoer G. Influence of Anti-idiotypic HAMA on Three Different Tumor Marker Assays in Ovarian Cancer Patients. *J of Nucl Med* 1993; 34(5): 126, Abstract Book, Proceedings of the 40th Annual Nuclear Medicine Meeting.
2. Nelson EL, Nanci A, Alexander T, Kamrud K, Fralish B, and Smith J. Alphavirus replicon particles (VRP) with dendritic cell (DC) tropism and expressing a designed rat neu target antigen overcome tolerance and induce anti-tumor immunity in a rat mammary tumor model. Abstract #1999, Proceedings of the American Association for Cancer Research (AACR), Volume 44, March 2003

LANGUAGES

Fluent in English, German and Romanian, Limited Spanish.